The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jay Olson - Oppenheimer & Co Inc - Analyst
: Oh, hey, congrats on all the progress, and thank you for taking our question. That NKTR-255 data in collaboration with Stanford looks great. Can
you talk about the next steps and if there's potential synergy for NKTR-255 with CAR-T for autoimmune diseases? Thank you.
Question: Jay Olson - Oppenheimer & Co Inc - Analyst
: Super helpful. Thank you very much.
Question: Jay Olson - Oppenheimer & Co Inc - Analyst
: Okay. Great. Really impressive data. Thank you again.
Question: Andy Shea - William Blair - Analyst
: Hi. Thanks for taking our question. So the book paper is pretty intriguing. I'm curious about your interpretation of the historical controls. Just given
the non-randomized nature of the study. There are some push and pulls regarding baseline patient characteristics. It seems like the historical
control might be a little bit more heavily pretreated, dosing is a little bit lower. So I'm just curious, just looking at the baseline characteristics, how
would you characterize the similarities and differences? How alike are those two populations? Thank you.
Question: Andy Shea - William Blair - Analyst
: That's helpful. Thank you.
Question: Arthur He - H.C. Wainwright & Co LLC - Analyst
: Hey, good afternoon, Howard and team. I just had a quick question on the 165. Obviously, it's very interesting preclinical data. Maybe, JZ, could
you give us more color on the 165, the binding to the Tregs receptor, but not the other ones on the CD4 T cell or on the monocyte? Because we
know the team FR2 also expressed on those two cells. Just curious about the connection there. Thanks.
Question: Arthur He - H.C. Wainwright & Co LLC - Analyst
: Great. Thanks.
| 
